Clinical Trial

Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this Phase 2 study is to investigate the efficacy and safety of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) infusion in patients undergoing VATS (Video-Assisted Thoracoscopic Surgery) or RATS (Robotic-Assisted Thoracoscopic Surgery) resection of Stage I-II non-small cell lung cancer (NSCLC).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-12-01; most recent amendment 2026-04-16.
Status change: Not Yet Recruiting → Recruiting 2025-12-12
Trial Details
NCT Number NCT07276789
Lead Sponsor Integro Theranostics
Conditions Non Small Cell Lung Cancer (NSCLC)
Enrollment 35 participants
Start Date 2025-12-08
Primary Completion 2026-08 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-20